Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Dan Gabriel Duda, Ph.D., D.M.D.

Co-Author

This page shows the publications co-authored by Dan Duda and Lipika Goyal.
Connection Strength

2.167
  1. Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. Clin Cancer Res. 2020 12 01; 26(23):6158-6167.
    View in: PubMed
    Score: 0.892
  2. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. J Immunother Cancer. 2020 11; 8(2).
    View in: PubMed
    Score: 0.226
  3. Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy. NPJ Precis Oncol. 2018; 2:22.
    View in: PubMed
    Score: 0.196
  4. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. 2019 01 01; 25(1):80-89.
    View in: PubMed
    Score: 0.194
  5. Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer. Int J Radiat Oncol Biol Phys. 2018 08 01; 101(5):1222-1225.
    View in: PubMed
    Score: 0.189
  6. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer. 2017 06 01; 123(11):1979-1988.
    View in: PubMed
    Score: 0.174
  7. Chemotherapy and antiangiogenics in biliary tract cancer. Lancet Oncol. 2015 Aug; 16(8):882-3.
    View in: PubMed
    Score: 0.156
  8. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jul 01; 5(7):1020-1027.
    View in: PubMed
    Score: 0.051
  9. FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer. 2019 07 01; 125(13):2213-2221.
    View in: PubMed
    Score: 0.050
  10. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology. 2014 Nov; 60(5):1776-82.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.